Meeting
2014 ASCO Annual Meeting
Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition.
Authors
Katharina Endhardt
The University of Chicago, Chicago, IL
Katharina Endhardt , Arun Khattri , Michaela K. Keck , Zhixiang Zuo , Damian Rieke , Anna Lena Ress , Johannes Braegelmann , Kelley Leung , Derya Mahmutoglu , Everett E. Vokes , Tanguy Y. Seiwert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6034)
DOI
10.1200/jco.2014.32.15_suppl.6034
Abstract #
6034
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC).
First Author: T. Rampias
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
First Author: Razia Aslam
Poster
2022 ASCO Annual Meeting
A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Glenn J. Hanna
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates